Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab.
Aged
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Brain Neoplasms
/ diagnosis
Carcinoma, Squamous Cell
/ diagnosis
Diagnostic Errors
Eccrine Porocarcinoma
/ diagnosis
Female
Humans
Leg
Lymphatic Metastasis
Pelvis
Skin Neoplasms
/ diagnosis
Sweat Gland Neoplasms
/ diagnosis
Treatment Outcome
dermatology
skin cancer
therapeutic indications
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
05 Sep 2019
05 Sep 2019
Historique:
entrez:
8
9
2019
pubmed:
8
9
2019
medline:
11
2
2020
Statut:
epublish
Résumé
A 67-year-old woman presented in 2012 with a crusty nodule on the left lower limb. Histopathological examination at this time reported a poorly differentiated squamous cell carcinoma (SCC). Two years later, she underwent lymphadenectomy and radiotherapy due to unilateral inguinal and pelvic sidewall nodal metastases. The following year she required excision of two subcutaneous lesions, reported pathologically to be SCC metastases. Further imaging following cyberknife radiotherapy to new brain metastases demonstrated widespread metastatic visceral disease. Twelve cycles of carboplatin and capecitabine failed to halt disease progression. In February 2017, she commenced pembrolizumab, achieving an excellent response and currently has no clinical or radiological evidence of disease. Given the unusual behaviour of her cancer, a histopathological review was requested. The diagnosis was revised to that of porocarcinoma (PC). This represents the first documented case of PC treated with immunotherapy. As of March 2019, the patient remains free of disease.
Identifiants
pubmed: 31492726
pii: 12/9/e228917
doi: 10.1136/bcr-2018-228917
pmc: PMC6731908
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
pembrolizumab
DPT0O3T46P
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Aust N Z J Surg. 1992 Sep;62(9):697-701
pubmed: 1520151
Case Rep Dermatol. 2014 Jun 27;6(2):159-63
pubmed: 25076888
Br J Dermatol. 1982 Dec;107(6):675-80
pubmed: 6293528
Ann Med Surg (Lond). 2017 Jun 20;20:74-79
pubmed: 28721214
Arch Dermatol. 1963 Nov;88:597-606
pubmed: 14060075
Ann Oncol. 2001 Mar;12(3):411-4
pubmed: 11332156
Br J Dermatol. 2016 Dec;175(6):1382-1386
pubmed: 27059424
Am J Surg Pathol. 2001 Jun;25(6):710-20
pubmed: 11395548
Ann Dermatol Venereol. 1993;120(1):107-15
pubmed: 8338322
Dermatol Surg. 2015 Jul;41(7):853-4
pubmed: 26079590
J Clin Oncol. 2010 Aug 20;28(24):e412-4
pubmed: 20406935
Cancer Chemother Pharmacol. 2010 May;66(1):151-8
pubmed: 19774377
Anticancer Res. 2014 Oct;34(10):5263-8
pubmed: 25275018
N Engl J Med. 2001 Mar 29;344(13):975-83
pubmed: 11274625
Laryngoscope. 2005 May;115(5):870-5
pubmed: 15867656
Cancer. 1985 Sep 1;56(5):1147-62
pubmed: 2990667
J Natl Cancer Inst. 1992 Feb 19;84(4):235-41
pubmed: 1734084
J Am Acad Dermatol. 1996 Nov;35(5 Pt 2):860-4
pubmed: 8912607
G Ital Dermatol Venereol. 2017 Feb;152(1):66-70
pubmed: 25236317
J Clin Oncol. 2005 Feb 1;23(4):759-65
pubmed: 15681519
Future Oncol. 2015;11(4):714
pubmed: 25686124
Kaohsiung J Med Sci. 2009 Jul;25(7):401-4
pubmed: 19605333
JAMA Dermatol. 2017 Jan 1;153(1):92-94
pubmed: 27784038
JAMA Dermatol. 2016 Jan;152(1):106-8
pubmed: 26422398
Arch Dermatol. 1983 Feb;119(2):104-14
pubmed: 6297408
Br J Dermatol. 2011 Nov;165(5):985-9
pubmed: 21711331